AgomAb Therapeutics NV American Depositary Shares (AGMB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AgomAb Therapeutics NV American Depositary Shares (AGMB) has a cash flow conversion efficiency ratio of -0.085x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.44 Million) by net assets ($146.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AgomAb Therapeutics NV American Depositary Shares - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how AgomAb Therapeutics NV American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of AgomAb Therapeutics NV American Deposita for a breakdown of total debt and financial obligations.
AgomAb Therapeutics NV American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AgomAb Therapeutics NV American Depositary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanjing University Environmental
SHE:300864
|
0.007x |
|
Olympic Steel Inc
NASDAQ:ZEUS
|
-0.009x |
|
Tactile Systems Technology Inc
NASDAQ:TCMD
|
-0.002x |
|
Dezhou United Petroleum Technology Co.Ltd.
SHE:301158
|
0.014x |
|
Flushing Financial Corporation
NASDAQ:FFIC
|
0.028x |
|
Boryung Pharm
KO:003850
|
0.060x |
|
Kyverna Therapeutics, Inc. Common Stock
NASDAQ:KYTX
|
-0.144x |
|
Eikon Therapeutics, Inc. Common Stock
NASDAQ:EIKN
|
0.047x |
Annual Cash Flow Conversion Efficiency for AgomAb Therapeutics NV American Depositary Shares (2022–2025)
The table below shows the annual cash flow conversion efficiency of AgomAb Therapeutics NV American Depositary Shares from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see AGMB market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $130.90 Million | $-51.74 Million | -0.395x | -58.76% |
| 2024-12-31 | $188.08 Million | $-46.83 Million | -0.249x | -53.32% |
| 2023-12-31 | $151.44 Million | $-24.59 Million | -0.162x | +43.28% |
| 2022-12-31 | $66.25 Million | $-18.97 Million | -0.286x | -- |
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenos… Read more